Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / XERS - NetworkNewsBreaks - Xeris Pharmaceuticals Inc. (NASDAQ: XERS) Featured in Mizuho Securities Research Report


XERS - NetworkNewsBreaks - Xeris Pharmaceuticals Inc. (NASDAQ: XERS) Featured in Mizuho Securities Research Report

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We applied a weighted average valuation methodology (DCF+EV/Sales) to derive our $18PT. Our assumptions include: Launch of the glucagon rescue pen in the U.S. market in 4Q19, with peak-sales of $399 mil in 2029. DCF Assumptions: Terminal value of 4.0x 2029 FCF and 13% discount rate to derive a $20 PT. EV/Sales Assumptions: 4.0x multiple of 2025 sales, discounted at 13% to derive a $16 PT. Additional pipeline indications represent upside to our current price target.”

To request access to the full report, visit http://nnw.fm/SaZ9d

About Xeris Pharmaceuticals Inc.

Xeris is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.

With a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke™. Its proprietary XeriSol™ and XeriJect™ formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris’ technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.

Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Stock Information

Company Name: Xeris Pharmaceuticals Inc.
Stock Symbol: XERS
Market: NASDAQ

Menu

XERS XERS Quote XERS Short XERS News XERS Articles XERS Message Board
Get XERS Alerts

News, Short Squeeze, Breakout and More Instantly...